ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial.

被引：0
|
作者：
Topham, James T. [1 ]
O'Callaghan, Christopher J. [2 ]
Feilotter, Harriet [3 ]
Kennecke, Hagen F. [4 ]
Lee, Young S. [5 ]
Li Weimin [6 ]
Banks, Kimberly [7 ]
Renouf, Daniel John [8 ]
Jonker, Derek [9 ]
Tu Dongsheng [2 ]
Chen, Eric Xueyu [10 ]
Loree, Jonathan M. [11 ]
机构：
[1] Genome Sci Ctr, Vancouver, BC, Canada
[2] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] MedImmune, Gaithersburg, MD USA
[6] AstraZeneca, Cambridge, MD USA
[7] Guardant Hlth Inc, Redwood City, CA USA
[8] BC Canc Agcy, Vancouver, BC, Canada
[9] Ottawa Hosp, Ottawa, ON, Canada
[10] Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] BC Canc, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
117
引用
收藏
页数：3
相关论文
共 19 条
  • [1] Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
    Ma, Lucy Xiaolu
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 183 - 183
  • [2] Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Bubie, Adrian
    Eluri, Madhulika
    Parseghian, Christine Megerdichian
    Overman, Michael J.
    Zhang, Nicole
    Drusbosky, Leylah
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 158 - 158
  • [3] Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial
    Ma, Lucy Xiaolu
    Titmuss, Emma
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Loree, Jonathan M.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial
    Ma, Lucy Xiaolu
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance
    Troiani, Teresa
    Zappavigna, Silvia
    Martinelli, Erika
    Addeo, Santolo R.
    Stiuso, Paola
    Ciardiello, Fortunato
    Caraglia, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) : 241 - 255
  • [6] RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC)
    Sunakawa, Yu
    Nakamura, Masato
    Ishizaki, Masahiro
    Kataoka, Masato
    Satake, Hironaga
    Kitazono, Masaki
    Yanagisawa, Hideyuki
    Kawamoto, Yasuyuki
    Kuramochi, Hidekazu
    Ohori, Hisatsugu
    Nakamura, Michio
    Maeda, Fumiyo
    Komeno, Chihiro
    Takeuchi, Masahiro
    Fujii, Masashi
    Yoshino, Takayuki
    Ichikawa, Wataru
    Tsuji, Akihito
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies n patients with metastatic colorectal cancer (mCRC)
    Sunakawa, Y.
    Nakamura, M.
    Ishizaki, M.
    Kataoka, M.
    Satake, H.
    Kitazono, M.
    Yanagisawa, H.
    Kawamoto, Y.
    Kuramochi, H.
    Ohori, H.
    Nakamura, M.
    Takahashi, K.
    Maeda, F.
    Komeno, C.
    Takeuchi, M.
    Fujii, M.
    Yoshino, T.
    Ichikawa, W.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 114 - 114
  • [8] Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial
    Takahashi, N.
    Izawa, N.
    Nishio, K.
    Masuishi, T.
    Shoji, H.
    Yamamoto, Y.
    Matsumoto, T.
    Sugiyama, K.
    Kajiwara, T.
    Kawakami, K.
    Aomatsu, N.
    Kawakami, H.
    Esaki, T.
    Narita, Y.
    Hara, H.
    Horie, Y.
    Boku, N.
    Miura, K.
    Moriwaki, T.
    Shimokawa, M.
    Nakajima, T.
    Muro, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S219 - S220
  • [9] Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
    Cremolini, Chiara
    Berenato, Rosa
    Morano, Federica
    Moretto, Roberto
    Perrone, Federica
    Tamborini, Elena
    Rossini, Daniele
    Gloghini, Annunziata
    Busico, Adele
    Fuca, Giovanni
    Baratelli, Chiara
    Tamburini, Emiliano
    Capone, Iolanda
    Volpi, Chiara Costanza
    Milione, Massimo
    Di Maio, Massimo
    Fontanini, Gabriella
    De Braud, Filippo
    Falcone, Alfredo
    Pietrantonio, Filippo
    CANCER RESEARCH, 2017, 77
  • [10] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    Yuki, Satoshi
    Yoshino, Takayuki
    Tsuchihara, Katsuya
    Shinozaki, Eiji
    Muro, Kei
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Akagi, Kiwamu
    Yamazaki, Kentaro
    Yamanaka, Takeharu
    Nomura, Shogo
    Fujii, Satoshi
    Esumi, Hiroyasu
    Abe, Yukiko
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12